Thrombolysis for acute ischemic stroke in the unwitnessed or extended therapeutic time window
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 3, 2019
- Accepted in final form September 30, 2019
- First Published December 31, 2019.
Article Versions
- Previous version (December 31, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Georgios Tsivgoulis, MD,
- Aristeidis H. Katsanos, MD,
- Konark Malhotra, MD,
- Amrou Sarraj, MD,
- Andrew D. Barreto, MD, MS,
- Martin Köhrmann, MD,
- Christos Krogias, MD,
- Niaz Ahmed, MD,
- Valeria Caso, MD,
- Peter D. Schellinger, MD and
- Andrei V. Alexandrov, MD
- Georgios Tsivgoulis, MD,
NONE
NONE
NONE
Journal of Neuroimaging, Associate Editor for Neurosonology, 2009- Stroke, Editorial Board Member, 2015-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aristeidis H. Katsanos, MD,
NONE
NONE
NONE
Journal of Neuroimaging, Editorial Board Member Stroke, Editorial Board Member PLOS One, Guest Academic Editor Frontiers in Neurology, Guest Editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Konark Malhotra, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Amrou Sarraj, MD,
Stryker Neurovascular - Commercial
NONE
Stryker Neurovascular - Commercial
Frontiers in Neurology - Associate Editor
NONE
NONE
NONE
Stryker Neurovascular - Commercial
Stryker Neurovascular - Commercial
NONE
NONE
Stryker Neurovascular - Commercial
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew D. Barreto, MD, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Köhrmann, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christos Krogias, MD,
NONE
NONE
honoraria for oral presentations or travel grants for scientific meetings from Bayer Vital, Daiichi-Sankyo, none related to this manuscript.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Niaz Ahmed, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am chairman of SITS International, which received grant from Boehringer-Ingelheim. SITS is currently conducting studies supported by Boehringer-Ingelheim as well as in collaboration with Karolinska Institutet, supported by Stryker, Covidien and Phenox.
I am coordinating a phase III clinical trial for which we have received grants provided by the Swedish Research Council
NONE
I am chairman of SITS International, which is financed directly and indirectly by grants from Karolinska Institutet, Stockholm County Council, the Swedish Heart-Lung Foundation, the Swedish Order of St. John, Friends of Karolinska Institutet, and private donors. I am also supported by grants provided by the Stockholm County Council.
NONE
NONE
NONE
NONE
NONE
NONE
- Valeria Caso, MD,
Respect ESUS Bayer SPI
NONE
Daichi-Sankyo BI Servier
NONE
NONE
NONE
NONE
NONE
speakerÂs bureau of Boehringer Ingelheim, Bayer, daichi- Sankyo, Ever Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter D. Schellinger, MD and
(1) Boehringer Ingelheim since 2003 (2) Daiichi Sankyo since 2014 (3) Cerevast until 2016 (4) Takeda 2017 (5) Portola 2019
NONE
(1) Boehringer Ingelheim since 2003 (2) Medtronic since 2015 (3) BMS/Pfizer since 2012 (4) Daiichi Sankyo since 2014 (5) Sun Pharma since 2016 (6) Cerevast until 2016 (7) Covidien until 2017
(1) Stroke (2006-2009) (2) Journal of Stroke (2012-today)
NONE
NeuroIntensiv eds 1-3, Springer, since 2008
NONE
(1) Boehringer Ingelheim since 2003 (2) Daiichi Sankyo since 2014 (3) Cerevast until 2016
(1) Boehringer Ingelheim since 2003 (2) Medtronic since 2015 (3) BMS/Pfizer since 2012 (4) Daiichi Sankyo since 2014 (5) Sun Pharma since 2016 (6) Cerevast until 2016 (7) Covidien until 2017
NONE
NONE
NONE
NINDS, NIH 2003-2004
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrei V. Alexandrov, MD
Commercial entity: Cerevast Therapeutics, Inc
NONE
NONE
Cerebrovascular Diseases, Editorial Board member, 2011- present Interventional Neurology, EB Member, 2016-present
ÂTherapeutic Methods and Apparatus for Use of Sonication to Enhance Perfusion of Tissue Inventors: Alexandrov AV, Aronowski J, Wojner AW US patent 6,733,450 (May 11, 2004) Assignee: Texas Systems, Board of Reagents
Alexandrov AV. Cerebrovascular Ultrasound in Stroke Prevention and Treatment. New York: Futura / Blackwell Publishing. 2003. ISBN 1- 4051-0381-7 Alexandrov AV. Cerebrovascular Ultrasound in Stroke Prevention and Treatment. Oxford: Blackwell Publishing (in Chinese) 2007. ISBN 7- 117-07389-6 Alexandrov AV. Cerebrovascular Ultrasound in Stroke Prevention and Treatment. (2nd Edition) Oxford: Wiley-Blackwell Publishers. 2011. 9781405195768.
NONE
Commercial entity: Cerevast Therapeutics, Inc.
Genentech, Inc
NONE
NONE
Commercial entity: Cerevast Therapeutics, Inc.
ZODIAC trial, NINR (R01 pending)
NONE
NONE
Commercial entity: Cerevast Therapeutics, Inc.
ÂTherapeutic Methods and Apparatus for Use of Sonication to Enhance Perfusion of Tissue Inventors: Alexandrov AV, Aronowski J, Wojner AW US patent 6,733,450 (May 11, 2004) Assignee: Texas Systems, Board of Reagents Source of payment: Cerevast Therapeutics, Inc.
ÂTherapeutic Methods and Apparatus for Use of Sonication to Enhance Perfusion of Tissue Inventors: Alexandrov AV, Aronowski J, Wojner AW US patent 6,733,450 (May 11, 2004) Assignee: Texas Systems, Board of Reagents Source of payment: Cerevast Therapeutics, Inc.
NONE
NONE
NONE
- From the Second Department of Neurology (G.T., A.H.K.), “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece; Department of Neurology (G.T., A.V.A.), University of Tennessee Health Science Center, Memphis; Department of Neurology (A.H.K., C.K.), St. Josef Hospital, Ruhr University Bochum, Germany; Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, Pennsylvania; Department of Neurology (A.S., A.D.B.), University of Texas Health Science Center, Houston; Department of Neurology (M.K.), Universitaetsklinikum Essen, Germany; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Stroke Unit and Division of Cardiovascular Medicine (V.C.), University of Perugia, Italy; and Departments of Neurology and Neurogeriatry (P.D.S.), Johannes Wesling Medical Center, Ruhr University Bochum, Minden, Germany.
- Correspondence
Dr. Tsivgoulis tsivgoulisgiorg{at}yahoo.gr
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Reader Response: Thrombolysis for acute ischemic stroke in the unwitnessed or extended therapeutic time window
- Koto Ishida, Neurologist, Associate Professor of Neurology, New York University (New York, NY)
Submitted January 02, 2020
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.